# Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)

> **NCT07716865** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Arctic Therapeutics** · enrollment: 15 (actual)

## Conditions studied

- Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
- Hemorrhage Brain
- Hemorrhage Cerebral

## Interventions

- **DRUG:** NACA

## Key facts

- **NCT ID:** NCT07716865
- **Lead sponsor:** Arctic Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-03
- **Primary completion:** 2026-12-29
- **Final completion:** 2027-01-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07716865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07716865, "Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07716865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*